In recent decades, great progress has been made in immunotherapy for advanced cancer leading to a substantial survival benefit in multiple solid tumors, including gastric, liver, NSCLC, etc. We investigated the expression levels of programmed cell death ligand‐1 (PD‐L1) in 852 rare tumor patients, finding a prevalence of 47.8% positivity, which is higher than the prevalence found in common cancers with approved indications for immunotherapy (Wang et al, 2021). Here, CD274 is linked to cancer.